Tolerability of ramipril 10 mg daily in high-risk cardiovascular patients in Taiwan: Experience from Kaohsiung Medical University Chung-Ho Memorial Hospital

Kaohsiung Journal of Medical Sciences

Volumn 21, Issue 11, 2005, Pages 511-516

  Chu, Chih Sheng ^a   Cheng, Kai Hung ^a   Lee, Kun Tai ^a   Lin, Tsung Hsien ^a   Lee, Shuo Tsan ^a   Su, Ho Ming ^a   Voon, Wen Choi ^a   Sheu, Sheng Hsiung ^a   Lai, Wen Ter ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

ACE inhibitor; Adverse effect; Tolerability

Indexed keywords

RAMIPRIL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIZZINESS; DRUG DOSE REGIMEN; DRUG TOLERABILITY; EDEMA; EPIGASTRIC PAIN; EPISTAXIS; FEMALE; FOLLOW UP; HEADACHE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPOTENSION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; NAUSEA; PARESTHESIA; POTASSIUM BLOOD LEVEL; PRESCRIPTION; RASH; SHOCK; SIDE EFFECT; STROKE; TAIWAN; THIRST; THORAX DISEASE; TITRIMETRY; TREATMENT WITHDRAWAL; UNIVERSITY HOSPITAL;

EID: 29044435064     PISSN: 02575655     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1607-551x(09)70159-7     Document Type: Article

References (17)

1. Vuong AD, Annis LG. Ramipril for the prevention and treatment of cardiovascular disease. Ann Pharmacother 2003;37:412-9.
2. Warner GT, Perry CM. Ramipril: a review of its use in the prevention of cardiovascular outcomes. Drugs 2002;62:1381-405.
3. Kleinert S. HOPE for cardiovascular disease prevention with ACE-inhibitor ramipril. Heart Outcomes Prevention Evaluation. Lancet 1999;354:841.
4. Arnold JM, Yusuf S, Young J, et al. Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003;107:1284-90.
5. Gerstein HC. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes Metab Res Rev 2002;18:S82-5.
6. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
7. Carroll CA, Coen MM, Rymer MM. Assessment of the effect of ramipril therapy on direct health care costs for first and recurrent strokes in high-risk cardiovascular patients using data from the Heart Outcomes Prevention Evaluation (HOPE) study. Clin Ther 2003;25:1248-61.
8. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
9. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000;101:1372-8.
10. Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-69.
11. Singh NP, Uppal M, Anuradha S, et al. Angiotensin converting enzyme inhibitors and cough - a north Indian study. J Assoc Physicians India 1998;46:448-51.
12. Wu N, Zhu JR, Chen KA. Tolerability of ramipril 10 mg/day in high-risk cardiovascular Chinese patients. Clin Drug Invest 2002;22:771-81.
13. Carre A, Vasmant D, Elmalem J, et al. Tolerability of ramipril in a multicenter study of mild-to-moderate hypertension in general practice. J Cardiovasc Pharmacol 1991;18:S141-3.
14. Mukae S, Itoh S, Aoki S, et al. Association of polymorphisms of the renin-angiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough. J Hum Hypertens 2002;16:857-63.
15. Lee YJ, Tsai JC. Angiotensin-converting enzyme gene insertion/deletion, not bradykinin B2 receptor -58T/C gene polymorphism, associated with angiotensin-converting enzyme inhibitor-related cough in Chinese female patients with non-insulin-dependent diabetes mellitus. Metabolism 2001;50:1346-50.
16. Furuya K, Yamaguchi E, Hirabayashi T, et al. Angiotensin-I-converting enzyme gene polymorphism and susceptibility to cough. Lancet 1994;343:354.
17. Ding PY, Hu OY, Pool PE, et al. Does Chinese ethnicity affect the pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors? J Hum Hypertens 2000;14:163-70.